Nanomaterials for Drug Delivery

Nanometer-scale polymeric materials are increasingly used to surmount the barriers faced by drugs and vaccines on their way to their site of action. All drugs face several transport barriers on their tortuous journey from their site of introduction to their molecular site of action. Critical barriers include rapid filtration in the kidney and clearance via the reticulo-endothelial system (RES)—particularly for drugs that spend a lot of time in the bloodstream—as well as transport from the bloodstream to target cells within tissues. At the tissue or cellular target, the drug must cross the plasma membrane, and within the cell, it must escape the harsh acidic environment of endolysosomes, within which biomolecular drugs such as proteins and oligonucleotides may be inactivated or degraded. Other barriers are the nuclear membrane and the multiple drug resistance mechanisms that pathological cells can develop. Recent studies illustrate some particularly promising ways in which nanomaterials as drug or vaccine carriers can assist in navigating these barriers, with a particular focus on administration by injection.

[1]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[2]  Dennis E Discher,et al.  Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. , 2009, Molecular pharmaceutics.

[3]  Ashutosh Chilkoti,et al.  Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumors after a single injection , 2009, Nature materials.

[4]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[5]  J. Hubbell,et al.  Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. , 2010, Vaccine.

[6]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[7]  Willem P C Stemmer,et al.  A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.

[8]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[9]  Yu Matsumoto,et al.  Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting , 2011, Science Translational Medicine.

[10]  Shawn M. Douglas,et al.  A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads , 2012, Science.

[11]  J. Hubbell,et al.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination , 2011, Proceedings of the National Academy of Sciences.

[12]  Dai Fukumura,et al.  Scaling rules for diffusive drug delivery in tumor and normal tissues , 2011, Proceedings of the National Academy of Sciences.

[13]  Erkki Ruoslahti,et al.  Targeting atherosclerosis by using modular, multifunctional micelles , 2009, Proceedings of the National Academy of Sciences.

[14]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[15]  A. Chilkoti,et al.  In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation , 2010, Proceedings of the National Academy of Sciences.

[16]  A. Bobkov,et al.  Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide , 2011, Proceedings of the National Academy of Sciences.

[17]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.